Table 2.
Eicosanoids associated with incident AF (FDR < 0.05).
| Eicosanoids# | Putative identity | Primary model* | Exploratory model* | ||||
|---|---|---|---|---|---|---|---|
| HR† | 95% CI† | P value† | HR† | 95% CI† | P value† | ||
| 293.21136/5.1237 | 9-oxoODE | 1.22 | 1.10–1.36 | 1.8 × 10–4 | 1.20 | 1.08–1.34 | 8.2 × 10–4 |
| 299.25921/5.5568 | EIC_33 | 1.16 | 1.07–1.27 | 6.9 × 10–4 | 1.25 | 1.04–1.25 | 4.2 × 10–3 |
| 265.17938/3.7720 | 12(R) HETE | 1.19 | 1.07–1.32 | 8.8 × 10–4 | 1.32 | 1.07–1.32 | 1.2 × 10–3 |
| 291.19445/4.3834 | 9-oxoOTrE | 1.19 | 1.07–1.31 | 9.8 × 10–4 | 1.31 | 1.07–1.31 | 1.5 × 10–3 |
| 321.24360/6.1182 | 15 oxoEDE | 1.18 | 1.07–1.29 | 1.0 × 10–3 | 1.28 | 1.05–1.28 | 4.0 × 10–3 |
| 321.24387/5.4933 | HETrE [M-H] | 1.17 | 1.06–1.29 | 1.6 × 10–3 | 1.27 | 1.04–1.27 | 5.8 × 10–3 |
#Each eicosanoid is represented by MZ/RT; MZ is the mass-to-charge ratio (to 5 decimals) and RT is the retention time (to 4 decimals).
*Primary model was adjusted for age, sex, height, weight, systolic and diastolic blood pressure, current smoking, use of antihypertensive medication, diabetes, history of myocardial infarction, and history of heart failure; Exploratory model was additionally adjusted for CRP and IL-6 concentration.
†HR Hazard ratio expressed per standard deviation of log transformed normalized eicosanoid concentration, CI Confidence interval; P value was not adjusted for multiple testing.